CRON Stock Overview
Operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Risk Analysis
No risks detected for CRON from our risk checks.
Cronos Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.01 |
| 52 Week High | CA$3.14 |
| 52 Week Low | CA$1.85 |
| Beta | 1.01 |
| 11 Month Change | -5.63% |
| 3 Month Change | -12.99% |
| 1 Year Change | 0.50% |
| 33 Year Change | -58.21% |
| 5 Year Change | -70.70% |
| Change since IPO | 1,118.18% |
Recent News & Updates
Recent updates
Buy Cronos Stock Before It Surges Higher
Aug 20Cronos Group: An Intriguing Value Opportunity
Jun 17Cronos Stock: Attractive Now With Cannabis Legalization In Germany
Mar 04Cronos Group: Flush With Cash And Trading Below Book Value
Feb 11Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M
Aug 09Cronos Group: Too Much Cash, Too Soon - Making The Bear Case
Aug 01Cronos Group: High Hurdles
May 11Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth
Mar 01Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids
Feb 22Cronos Group: Still No Reason To Own
Jan 22Cronos Group Strategic Investor Altria May Be About To Buy The Balance
Nov 08After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?
Aug 30Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement
Jul 12Cronos Group stock rises 2.6% with acquisition of 10.5% stake in PharmaCann
Jun 14Cronos Group: Still Hasn't Launched
May 09Cronos Group Q1 Earnings Preview
May 06Cronos: The Most Confusing Cannabis Stock
Apr 28Cronos: Sitting On Your Hands Is Not A Winning Strategy
Jan 03Cronos Group (CRON) Investor Presentation - Slideshow
Nov 24Cronos Is A Buy With Increasing Revenues
Nov 18Cronos shares rise 5% on solid Q3 beat; top-line +96% boosted by advancement in Canadian/Israeli market
Nov 05Cronos: Failure To Launch
Nov 03Shareholder Returns
| CRON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.4% | -3.8% | -1.0% |
| 1Y | 0.5% | 9.8% | 30.3% |
Return vs Industry: CRON underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: CRON underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CRON's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 356 | Mike Gorenstein | www.thecronosgroup.com |
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Cronos Group Inc. Fundamentals Summary
| CRON fundamental statistics | |
|---|---|
| Market cap | US$773.83m |
| Earnings (TTM) | -US$47.56m |
| Revenue (TTM) | US$111.23m |
6.9x
P/S Ratio-16.0x
P/E RatioIs CRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRON income statement (TTM) | |
|---|---|
| Revenue | US$111.23m |
| Cost of Revenue | US$87.81m |
| Gross Profit | US$23.42m |
| Other Expenses | US$70.98m |
| Earnings | -US$47.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 21.06% |
| Net Profit Margin | -42.76% |
| Debt/Equity Ratio | 0% |
How did CRON perform over the long term?
See historical performance and comparison